The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Biomarkers for prostate cancer: prostate-specific antigen and beyond
Abstract
In recent years, several new biomarkers supplementing the role of prostate-specific antigen (PSA) have become available for men with prostate cancer. Although widely used in an ad hoc manner, the role of PSA in screening asymptomatic men for prostate cancer is controversial. Several expert panels, however, have recently recommended limited PSA screening following informed consent in average-risk men, aged 55–69 years. As a screening test for prostate cancer however, PSA has limited specificity and leads to overdiagnosis which in turn results in overtreatment. To increase specificity and reduce the number of unnecessary biopsies, biomarkers such as percent free PSA, prostate health index (PHI) or the 4K score may be used, while Progensa PCA3 may be measured to reduce the number of repeat biopsies in men with a previously negative biopsy. In addition to its role in screening, PSA is also widely used in the management of patients with diagnosed prostate cancer such as in surveillance following diagnosis, monitoring response to therapy and in combination with both clinical and histological criteria in risk stratification for recurrence. For determining aggressiveness and predicting outcome, especially in low- or intermediate-risk men, tissue-based multigene tests such as Decipher, Oncotype DX (Prostate), Prolaris and ProMark, may be used. Emerging therapy predictive biomarkers include AR-V7 for predicting lack of response to specific anti-androgens (enzalutamide, abiraterone), BRAC1/2 mutations for predicting benefit from PARP inhibitor and PORTOS for predicting benefit from radiotherapy. With the increased availability of multiple biomarkers, personalised treatment for men with prostate cancer is finally on the horizon.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Screening and Prostate-Cancer Mortality in a Randomized European Study
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810084 · Cited by 4,014
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408
Ahmed, H. U., El-Shater Bosaily, A., Brown, L. C., Gabe, R., Kaplan, R., Parmar, M. K., Collaco-Moraes, Y., Ward, K., Hindley, R. G., Freeman, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32401-1 · Cited by 3,284
Mottet, N., Bellmunt, J., Bolla, M., Briers, E., Cumberbatch, M. G., De Santis, M., Fossati, N., Gross, T., Henry, A. M., Joniau, S., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.08.003 · Cited by 3,227
Natural History of Progression After PSA Elevation Following Radical Prostatectomy
Pound, C. R. (1999) · JAMA · doi:10.1001/jama.281.17.1591 · Cited by 3,071
Mortality Results from a Randomized Prostate-Cancer Screening Trial
Andriole, G. L., Crawford, E. D., Grubb, R. L., Buys, S. S., Chia, D., Church, T. R., Fouad, M. N., Gelmann, E. P., Kvale, P. A., Reding, D. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810696 · Cited by 2,906
Roach, M., Hanks, G., Thames, H., Schellhammer, P., Shipley, W. U., Sokol, G. H., & Sandler, H. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.04.029 · Cited by 2,749
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-2-201207170-00459 · Cited by 2,522
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C., Basch, E., Fizazi, K., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,654
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Zappa, M., Nelen, V., Kwiatkowski, M., Lujan, M., Määttänen, L., Lilja, H., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60525-0 · Cited by 1,566
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D’Amico, A. V., Davis, B. J., Dorff, T., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0023 · Cited by 1,532
Cornford, P., Bellmunt, J., Bolla, M., Briers, E., De Santis, M., Gross, T., Henry, A. M., Joniau, S., Lam, T. B., Mason, M. D., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.08.002 · Cited by 1,438
Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Grossman, D. C., Curry, S. J., Owens, D. K., Bibbins-Domingo, K., Caughey, A. B., Davidson, K. W., Doubeni, C. A., Ebell, M., Epling, J. W., et al. (2018) · JAMA · doi:10.1001/jama.2018.3710 · Cited by 1,436
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Smith, M. R., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B. A., Graff, J. N., Olmos, D., Mainwaring, P. N., Lee, J. Y., Uemura, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1715546 · Cited by 1,344
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer
Donovan, J. L., Hamdy, F. C., Lane, J. A., Mason, M., Metcalfe, C., Walsh, E., Blazeby, J. M., Peters, T. J., Holding, P., Bonnington, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606221 · Cited by 1,338
Prostate-Cancer Mortality at 11 Years of Follow-up
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113135 · Cited by 1,245
A Preoperative Nomogram for Disease Recurrence Following Radical Prostatectomy for Prostate Cancer
Kattan, M. W., Eastham, J. A., Stapleton, A. M. F., Wheeler, T. M., & Scardino, P. T. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.10.766 · Cited by 1,242
Catalona, W. J., Partin, A. W., Slawin, K. M., Brawer, M. K., Flanigan, R. C., Patel, A., Richie, J. P., deKernion, J. B., Walsh, P. C., Scardino, P. T., et al. (1998) · JAMA · doi:10.1001/jama.279.19.1542 · Cited by 1,162
Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brünner, N., Chan, D. W., Babaian, R., Bast, R. C., Dowell, B., Esteva, F. J., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.105601 · Cited by 1,129
Self-citationAndriole, G. L., Crawford, E. D., Grubb, R. L., Buys, S. S., Chia, D., Church, T. R., Fouad, M. N., Isaacs, C., Kvale, P. A., Reding, D. J., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr500 · Cited by 1,121
Small, E. J., Schellhammer, P. F., Higano, C. S., Redfern, C. H., Nemunaitis, J. J., Valone, F. H., Verjee, S. S., Jones, L. A., & Hershberg, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5252 · Cited by 1,108
DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.
Bussemakers, M. J. G., van Bokhoven, A., Verhaegh, G. W. C. T., Smit, F. P., Karthaus, H. F. M., Schalken, J. A., Debruyne, F. M. J., Ru, N., & Isaacs, W. B. (1999) · PubMed · Cited by 1,051
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Hussain, M., Fizazi, K., Saad, F., Rathenborg, P., Shore, N., Ferreira, U., Ivashchenko, P., Demirhan, E., Modelska, K., Phung, D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800536 · Cited by 1,035
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Fizazi, K., Shore, N., Tammela, T. L., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1815671 · Cited by 930
Sanda, M. G., Cadeddu, J. A., Kirkby, E., Chen, R. C., Crispino, T., Fontanarosa, J., Freedland, S. J., Greene, K. L., Klotz, L. H., Makarov, D. V., et al. (2017) · The Journal of Urology · doi:10.1016/j.juro.2017.11.095 · Cited by 830
DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer
Hessels, D., Klein Gunnewiek, J. M. T., van Oort, I., Karthaus, H. F. M., van Leenders, G. J. L., van Balken, B., Kiemeney, L. A., Witjes, J. A., & Schalken, J. A. (2003) · European Urology · doi:10.1016/s0302-2838(03)00201-x · Cited by 704
A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer
Hugosson, J., Roobol, M. J., Månsson, M., Tammela, T. L. J., Zappa, M., Nelen, V., Kwiatkowski, M., Lujan, M., Carlsson, S. V., Talala, K. M., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.02.009 · Cited by 698
Klein, E. A., Cooperberg, M. R., Magi-Galluzzi, C., Simko, J. P., Falzarano, S. M., Maddala, T., Chan, J. M., Li, J., Cowan, J. E., Tsiatis, A. C., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.05.004 · Cited by 659
(1997) · British Journal of Urology · doi:10.1046/j.1464-410x.1997.d01-6840.x · Cited by 654
Clinical implications of PTEN loss in prostate cancer
Jamaspishvili, T., Berman, D. M., Ross, A. E., Scher, H. I., De Marzo, A. M., Squire, J. A., & Lotan, T. L. (2018) · Nature Reviews Urology · doi:10.1038/nrurol.2018.9 · Cited by 651
Gillessen, S., Attard, G., Beer, T. M., Beltran, H., Bossi, A., Bristow, R., Carver, B., Castellano, D., Chung, B. H., Clarke, N., et al. (2018) · European Urology · doi:10.1016/j.eururo.2017.06.002 · Cited by 642
Ilic, D., Djulbegovic, M., Jung, J. H., Hwang, E. C., Zhou, Q., Cleves, A., Agoritsas, T., & Dahm, P. (2018) · BMJ · doi:10.1136/bmj.k3519 · Cited by 641
Stephenson, A. J., Scardino, P. T., Eastham, J. A., Bianco, F. J., Dotan, Z. A., Fearn, P. A., & Kattan, M. W. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj190 · Cited by 623
Smith, R. A., Andrews, K. S., Brooks, D., Fedewa, S. A., Manassaram‐Baptiste, D., Saslow, D., Brawley, O. W., & Wender, R. C. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21446 · Cited by 571
Fenton, J. J., Weyrich, M. S., Durbin, S., Liu, Y., Bang, H., & Melnikow, J. (2018) · JAMA · doi:10.1001/jama.2018.3712 · Cited by 555
Adib, R., Anderson, J., Ashken, M. H., Baumber, C. D., CRA, B. D., BEYNON, L. L., Blaxland, J. W., Boag, V., Bolger, J., Boreham, J., et al. (1997) · Kent Academic Repository (University of Kent) · Cited by 551
APTIMA PCA3 Molecular Urine Test: Development of a Method to Aid in the Diagnosis of Prostate Cancer
Groskopf, J., Aubin, S. M., Deras, I. L., Blase, A., Bodrug, S., Clark, C., Brentano, S., Mathis, J., Pham, J., Meyer, T., et al. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2005.063289 · Cited by 529
Van den Broeck, T., van den Bergh, R. C. N., Arfi, N., Gross, T., Moris, L., Briers, E., Cumberbatch, M., De Santis, M., Tilki, D., Fanti, S., et al. (2019) · European Urology · doi:10.1016/j.eururo.2018.10.011 · Cited by 523
Hussain, M., Tangen, C. M., Higano, C., Schelhammer, P. F., Faulkner, J., Crawford, E. D., Wilding, G., Akdas, A., Small, E. J., Donnelly, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4246 · Cited by 505
Smith, R. A., Manassaram-Baptiste, D., Brooks, D., Cokkinides, V., Doroshenk, M., Saslow, D., Wender, R. C., & Brawley, O. W. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21212 · Cited by 478
Antonarakis, E. S., Lu, C., Luber, B., Wang, H., Chen, Y., Zhu, Y., Silberstein, J. L., Taylor, M. N., Maughan, B. L., Denmeade, S. R., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.1961 · Cited by 466
Martin, R. M., Donovan, J. L., Turner, E. L., Metcalfe, C., Young, G. J., Walsh, E. I., Lane, J. A., Noble, S., Oliver, S. E., Evans, S., et al. (2018) · JAMA · doi:10.1001/jama.2018.0154 · Cited by 415
AMLING, C. L., BERGSTRALH, E. J., BLUTE, M. L., SLEZAK, J. M., & ZINCKE, H. (2001) · Journal of Urology · doi:10.1016/s0022-5347(05)66452-x · Cited by 408
Grönberg, H., Adolfsson, J., Aly, M., Nordström, T., Wiklund, P., Brandberg, Y., Thompson, J., Wiklund, F., Lindberg, J., Clements, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00361-7 · Cited by 407
Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment
Tomlins, S. A., Day, J. R., Lonigro, R. J., Hovelson, D. H., Siddiqui, J., Kunju, L. P., Dunn, R. L., Meyer, S., Hodge, P., Groskopf, J., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.04.039 · Cited by 393
Wyatt, A. W., Azad, A. A., Volik, S. V., Annala, M., Beja, K., McConeghy, B., Haegert, A., Warner, E. W., Mo, F., Brahmbhatt, S., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0494 · Cited by 373
Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker–Based Risk Score
Van Neste, L., Hendriks, R. J., Dijkstra, S., Trooskens, G., Cornel, E. B., Jannink, S. A., de Jong, H., Hessels, D., Smit, F. P., Melchers, W. J. G., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.04.012 · Cited by 370
Armstrong, A. J., Halabi, S., Luo, J., Nanus, D. M., Giannakakou, P., Szmulewitz, R. Z., Danila, D. C., Healy, P., Anand, M., Rothwell, C. J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01731 · Cited by 362
AMLING, C. L., BERGSTRALH, E. J., BLUTE, M. L., SLEZAK, J. M., & ZINCKE, H. (2001) · The Journal of Urology · doi:10.1097/00005392-200104000-00020 · Cited by 348
Risk Assessment for Prostate Cancer Metastasis and Mortality at the Time of Diagnosis
Cooperberg, M. R., Broering, J. M., & Carroll, P. R. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp122 · Cited by 336
Studer, U. E., Whelan, P., Albrecht, W., Casselman, J., de Reijke, T., Hauri, D., Loidl, W., Isorna, S., Sundaram, S. K., Debois, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7423 · Cited by 327
Cullen, J., Rosner, I. L., Brand, T. C., Zhang, N., Tsiatis, A. C., Moncur, J., Ali, A., Chen, Y., Knezevic, D., Maddala, T., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.11.030 · Cited by 310
The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer
Loeb, S., Sanda, M. G., Broyles, D. L., Shin, S. S., Bangma, C. H., Wei, J. T., Partin, A. W., Klee, G. G., Slawin, K. M., Marks, L. S., et al. (2015) · Journal of Urology · doi:10.1016/j.juro.2014.10.121 · Cited by 300
Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer?
Wei, J. T., Feng, Z., Partin, A. W., Brown, E., Thompson, I., Sokoll, L., Chan, D. W., Lotan, Y., Kibel, A. S., Busby, J. E., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.8505 · Cited by 274
Jansen, F. H., van Schaik, R. H. N., Kurstjens, J., Horninger, W., Klocker, H., Bektic, J., Wildhagen, M. F., Roobol, M. J., Bangma, C. H., & Bartsch, G. (2010) · European Urology · doi:10.1016/j.eururo.2010.02.003 · Cited by 259
Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials
Tsodikov, A., Gulati, R., Heijnsdijk, E. A. M., Pinsky, P. F., Moss, S. M., Qiu, S., de Carvalho, T. M., Hugosson, J., Berg, C. D., Auvinen, A., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2586 · Cited by 251
Vickers, A. J., Cronin, A. M., Aus, G., Pihl, C.-G., Becker, C., Pettersson, K., Scardino, P. T., Hugosson, J., & Lilja, H. (2008) · BMC Medicine · doi:10.1186/1741-7015-6-19 · Cited by 249
Spratt, D. E., Yousefi, K., Deheshi, S., Ross, A. E., Den, R. B., Schaeffer, E. M., Trock, B. J., Zhang, J., Glass, A. G., Dicker, A. P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.2811 · Cited by 247
Vickers, A., Cronin, A., Roobol, M., Savage, C., Peltola, M., Pettersson, K., Scardino, P. T., Schröder, F., & Lilja, H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.1968 · Cited by 235
Taneja, S. S. (2015) · Journal of Urology · doi:10.1016/j.juro.2015.02.070 · Cited by 228
Heller, G., McCormack, R., Kheoh, T., Molina, A., Smith, M. R., Dreicer, R., Saad, F., de Wit, R., Aftab, D. T., Hirmand, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.2998 · Cited by 228
Partin, A. W., Van Neste, L., Klein, E. A., Marks, L. S., Gee, J. R., Troyer, D. A., Rieger-Christ, K., Jones, J. S., Magi-Galluzzi, C., Mangold, L. A., et al. (2014) · Journal of Urology · doi:10.1016/j.juro.2014.04.013 · Cited by 226
Wei, L., Wang, J., Lampert, E., Schlanger, S., DePriest, A. D., Hu, Q., Gomez, E. C., Murakam, M., Glenn, S. T., Conroy, J., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.07.008 · Cited by 226
Duchesne, G. M., Woo, H. H., Bassett, J. K., Bowe, S. J., D'Este, C., Frydenberg, M., King, M., Ledwich, L., Loblaw, A., Malone, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00107-8 · Cited by 219
Lazzeri, M., Haese, A., de la Taille, A., Palou Redorta, J., McNicholas, T., Lughezzani, G., Scattoni, V., Bini, V., Freschi, M., Sussman, A., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.01.011 · Cited by 215
Seibert, T. M., Fan, C. C., Wang, Y., Zuber, V., Karunamuni, R., Parsons, J. K., Eeles, R. A., Easton, D. F., Kote-Jarai, Z., Al Olama, A. A., et al. (2018) · BMJ · doi:10.1136/bmj.j5757 · Cited by 215
Zhao, S. G., Chang, S. L., Spratt, D. E., Erho, N., Yu, M., Ashab, H. A.-D., Alshalalfa, M., Speers, C., Tomlins, S. A., Davicioni, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30491-0 · Cited by 213
Bryant, R. J., Sjoberg, D. D., Vickers, A. J., Robinson, M. C., Kumar, R., Marsden, L., Davis, M., Scardino, P. T., Donovan, J., Neal, D. E., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv095 · Cited by 184
Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis
Louie, K. S., Seigneurin, A., Cathcart, P., & Sasieni, P. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu525 · Cited by 183
Blume-Jensen, P., Berman, D. M., Rimm, D. L., Shipitsin, M., Putzi, M., Nifong, T. P., Small, C., Choudhury, S., Capela, T., Coupal, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2603 · Cited by 179
Biomarkers in prostate cancer – Current clinical utility and future perspectives
Kretschmer, A., & Tilki, D. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.11.007 · Cited by 167
on behalf of the Transatlantic Prostate Group, Cuzick, J., Stone, S., Fisher, G., Yang, Z. H., North, B. V., Berney, D. M., Beltran, L., Greenberg, D., Møller, H., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.223 · Cited by 155
Filella, X., & Giménez, N. (2012) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2012-0410 · Cited by 155
Stephan, C., Vincendeau, S., Houlgatte, A., Cammann, H., Jung, K., & Semjonow, A. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2012.195784 · Cited by 153
Auprich, M., Chun, F. K. ‐., Ward, J. F., Pummer, K., Babaian, R. J., Augustin, H., Luger, F., Gutschi, S., Budäus, L., Fisch, M. M., et al. (2010) · European Urology · doi:10.1016/j.eururo.2010.10.024 · Cited by 147
Bul, M., van den Bergh, R. C. N., Zhu, X., Rannikko, A. S., Vasarainen, H., Bangma, C. H., Schröder, F. H., & Roobol, M. J. (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.11434.x · Cited by 146
Emerging biomarkers in the diagnosis of prostate cancer
Filella, X., Fernández‐Galán, E., Fernández, R. M. S., & Foj, L. (2018) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s136026 · Cited by 143
Harshman, L. C., Chen, Y., Liu, G., Carducci, M. A., Jarrard, D. F., Dreicer, R., Hahn, N. M., Garcia, J. A., Hussain, M., Shevrin, D. H., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3921 · Cited by 139
Prostate Cancer Screening — A Perspective on the Current State of the Evidence
Pinsky, P. F., Prorok, P. C., & Kramer, B. S. (2017) · New England Journal of Medicine · doi:10.1056/nejmsb1616281 · Cited by 124
Gandaglia, G., Albers, P., Abrahamsson, P.-A., Briganti, A., Catto, J. W. F., Chapple, C. R., Montorsi, F., Mottet, N., Roobol, M. J., Sønksen, J., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.04.033 · Cited by 122
Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review
Lamy, P., Allory, Y., Gauchez, A., Asselain, B. J. R., Beuzeboc, P., de Crémoux, P., Fontugne, J., Georges, A., Hennequin, C., Lehmann‐Che, J., et al. (2017) · European Urology Focus · doi:10.1016/j.euf.2017.02.017 · Cited by 117
Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade Prostate Cancer
Mahal, B. A. V., Yang, D. D., Wang, N. Q., Alshalalfa, M., Davicioni, E., Choeurng, V., Schaeffer, E. M., Ross, A. E., Spratt, D. E., Den, R. B., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.01.043 · Cited by 112
Prognostic role of Ki-67 score in localized prostate cancer: A systematic review and meta-analysis
Berlín, A., Castro-Mesta, J. F., Rodríguez‐Romo, L., Barajas, D. H., González-Guerrero, J. F., Rodríguez-Fernández, I. A., Conchas, G. A. G., Verdines-Perez, A. M., & Vera-Badillo, F. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.05.004 · Cited by 107
Cui, Y., Cao, W., Li, Q., Shen, H., Liu, C., Deng, J., Xu, J., & Shao, Q. (2016) · Scientific Reports · doi:10.1038/srep25776 · Cited by 106
Braun, K., Sjoberg, D. D., Vickers, A. J., Lilja, H. G., & Bjartell, A. S. (2015) · European Urology · doi:10.1016/j.eururo.2015.04.028 · Cited by 104
Prostate cancer screening and the management of clinically localized disease
Wilt, T., & Ahmed, H. U. (2013) · BMJ · doi:10.1136/bmj.f325 · Cited by 104
Scattoni, V., Lazzeri, M., Giovanni Lughezzani, A., LUCA, S. D., Passera, R., Bollito, E., Randone, D. F., Abdollah, F., Umberto Capitanio, A., Larcher, A., et al. (2013) · The Journal of Urology · doi:10.1016/j.juro.2013.02.3184 · Cited by 103
Vickers, A. J., Gupta, A., Savage, C. J., Pettersson, K. S. I., Dahlin, A., Bjartell, A. S., Manjer, J., Scardino, P. T., Ulmert, D., & Lilja, H. G. (2011) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-1003 · Cited by 90
Gnanapragasam, V. J., Burling, K., George, A., Stearn, S., Warren, A. Y., Barrett, T., Koo, B., Gallagher, F. A., Doble, A., Kastner, C., et al. (2016) · Scientific Reports · doi:10.1038/srep35364 · Cited by 82
Russo, G. I., Regis, F., Castelli, T., Favilla, V., Privitera, S., Giardina, R., Cimino, S., & Morgia, G. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.12.022 · Cited by 81
Are multiple markers the future of prostate cancer diagnostics?
Mikolajczyk, S. D., Song, Y. S., Wong, J. R., Matson, R. S., & Rittenhouse, H. G. (2004) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2004.05.016 · Cited by 79
Huang, Y., Li, Z., Huang, Y.-L., Song, H.-J., & Wang, Y. (2018) · Medicine · doi:10.1097/md.0000000000010249 · Cited by 73
Gore, J. L., du Plessis, M., Santiago‐Jiménez, M., Yousefi, K., Thompson, D. J. S., Karsh, L. I., Lane, B. R., FRANKS, M. E., Chen, D. Y. T., Bandyk, M., et al. (2017) · Cancer · doi:10.1002/cncr.30665 · Cited by 71
Hoffman, R. M., Clanon, D. L., Littenberg, B., et al. (2000) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2000.90907.x · Cited by 67
Morris, M. J., Rumble, R. B., Basch, E., Hotte, S. J., Loblaw, A., Rathkopf, D. E., Celano, P., Bangs, R., & Milowsky, M. I. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.0619 · Cited by 57
epiCaPture: A Urine DNA Methylation Test for Early Detection of Aggressive Prostate Cancer
O’Reilly, E., Tuzova, A. V., Walsh, A. L., Russell, N. M., O’Brien, O., Kelly, S., Dhomhnalláin, O. N., DeBarra, L., Dale, C. M., Brugman, R., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00134 · Cited by 56
The utility of prostate‐specific antigen in the management of advanced prostate cancer
Crawford, E. D., Bennett, C. L., Andriole, G. L., Garnick, M. B., & Petrylak, D. P. (2013) · British Journal of Urology · doi:10.1111/bju.12061 · Cited by 54
Martin, R., Donovan, J., Turner, E., Metcalfe, C., Young, G., Walsh, E., Lane, J., Noble, S., Oliver, S., Evans, S., et al. (2018) · Apollo (University of Cambridge) · doi:10.17863/cam.24935 · Cited by 33
Gasińska, A., Jaszczyński, J., Rychlik, U., Łuczyńska, E., Pogodziński, M., & Mikolaj, P. (2019) · Pathology & Oncology Research · doi:10.1007/s12253-019-00659-4 · Cited by 32
Bauman, G. S., Breau, R. H., Kamel‐Reid, S., Louie, A. V., & Pautlere, S. (2017) · Scholarship@Western (Western University) · Cited by 8
Time for a “Radical” Change to Active Surveillance for Prostate Cancer?
Donovan, J., & Hamdy, F. C. (2018) · European Urology · doi:10.1016/j.eururo.2018.05.009 · Cited by 4
Cited by
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Metadata
- Authors
- Duffy, M. J.
- Venue
- Clinical Chemistry and Laboratory Medicine (CCLM)
- Publisher
- Walter de Gruyter GmbH
- Published
- 2019-11-12
- Volume
- 58
- Issue
- 3
- Pages
- 326-339
- ISSN
- 1434-6621 (ISSN-L)
- 1437-4331
- OpenAlex
- W2987712342
- Cited by
- 267
- References
- 103
- FWCI
- 12.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.